Compare Enveric Biosciences Inc (ENVB) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Freshworks Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Freshworks Inc trades at $11.97 (market cap $3.31B). The key difference: Freshworks Inc is far larger — about 533.9× Enveric Biosciences Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | FRSH | |
|---|---|---|
Market Cap | $6.20M | $3.31B |
Sector | Health | Technology |
52-Week High | $17.40 | $13.97 |
52-Week Low | $1.27 | $6.88 |
Enterprise Value | $1.30M | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Freshworks (FRSH) trades at $11.84, up 2.16% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.17 versus $0.13 expected, and revenue growth of 16% year-over-year. Recent developments include FedRAMP 'In-Process' status for Freshservice and a leadership appointment, reinforcing its competitive position in AI-powered service operations.
The stock offers upside to the $16.50 consensus price target, driven by robust fundamentals like a 20.49% net margin and 19.7% ROE. Risks include high EV/EBITDA valuation and dependence on SaaS sector growth. Analysts are evenly split between Buy and Hold ratings, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
